NOSEGMENTAR VITILIGODA IMMUNOMETABOLIK MARKERLAR VA KLINIK BELGILAR O‘RTASIDAGI BOG‘LIQLIK: SAMARQAND VILOYATI AHOLISI MISOLIDA
Maqola yon paneli
Maqolaning asosiy mazmuni
Abstrak
Dolzarbligi. Nosegmentar vitiligo surunkali polietiologik kasallik bo'lib, uning tarqalganligi butun dunyoda, ayniqsa Samarqand viloyati kabi insolyatsiyasi yuqori mintaqalarda ortib bormoqda. Kasallik Th1 vositachiligidagi yallig'lanishning faollashuvi, CXCL10 va IFN-γ darajasining oshishi, yaqqol oksidativ stress va metabolik buzilishlarni o'z ichiga olgan murakkab immunometabolik patogenez bilan tavsiflanadi. Immun, metabolik va antioksidant ko'rsatkichlarning vitiligo klinik belgilari bilan bog'liqligi yetarlicha o'rganilmagani, shuningdek xavf omillarining mintaqaviy xususiyatlari ushbu sohada keyingi tadqiqotlarning yuqori dolzarbligini belgilaydi. Tadqiqot maqsadi. Samarqand viloyati bemorlarida immunometabolik markerlarning nosegmentar vitiligo (NV) klinik belgilari bilan bog'liqligini baholash va kasallik faolligining eng ma'lumotli biomarkerlarini aniqlash. Materiallar va usullar. NV tashxisi qo'yilgan 112 bemor va 40 sog'lom ko'ngilli ishtirokida bir markazli ko'ndalang tadqiqot o'tkazildi. VASI va VIDA klinik indekslari, Fitspatrik bo'yicha fototip, kasallik davomiyligi baholandi. Laboratoriya parametrlari IFN-γ, IL-6, TNF-α, CXCL10 xemokini darajalarini (IFA), CD4+/CD8+/NK hujayralar subpopulyatsiyalarini (oqim sitometriyasi), oksidativ stress ko'rsatkichlarini (MDA, SOD, GPO), metabolik indekslarni (lipid profili, HOMA-IR) va vitamin D ni o'z ichiga oldi. Statistik tahlil t-test, Pirson korrelyatsion tahlili va ROC-tahlilni qamrab oldi (p<0,05). Natijalar. NV bilan og'rigan bemorlarda Th1 vositachiligidagi immun javobning yaqqol faollashuvi kuzatildi: IFN-γ, CXCL10, IL-6 va TNF-α nazoratdagiga qaraganda sezilarli yuqori bo'ldi (p<0,001). CXCL10 kasallik faolligini aniqlashda eng yaxshi diagnostik qobiliyatni ko'rsatdi (AUC = 0,91) va VASI hamda VIDA indekslari bilan yuqori korrelyatsiyaga ega bo'ldi. Oksidativ stressning sezilarli kuchayishi aniqlandi: MDA darajasi 2,3 baravardan ko'proq oshgan, SOD va GPO faolligi esa 35–42 % ga pasaygan. MDA va SOD ko'rsatkichlari klinik indekslar bilan korrelyatsiyalandi (mos ravishda r = 0,55 va r = –0,49). Bemorlarning 36,7 % ida insulinorezistentlik aniqlandi va u IL-6 hamda CXCL10 ning oshgan darajalari bilan bog'liq bo'ldi. Gipovitaminoz D holatlarning 71 % ida topildi va yaqqolroq yallig'lanish faolligi bilan birga kechdi. Xulosa. Samarqand viloyati bemorlarida nosegmentar vitiligo Th1-yallig'lanishning faollashuvi, antioksidant himoyaning buzilishi va metabolik nomutanosiblik bilan tavsiflanuvchi yaqqol immunometabolik profilga ega. CXCL10 vitiligo faolligining eng ma'lumotli biomarkeri hisoblanadi. Immunometabolik parametrlarni kompleks baholash kasallik faolligi darajasini obyektivlashtirish va davolash taktikasini shaxsiylashtirish uchun qo'llanilishi mumkin.
Maqola tafsilotlari
Nashr
Bo'lim
Ushbu asar Creative Commons Attribution 4.0 International litsenziyasi asosida litsenziyalangan.
Qanday iqtibos keltirish kerak
Adabiyotlar
Ezzedine K., Lim H.W., Suzuki T., et al. Vitiligo: A comprehensive overview. N Engl J Med. 2020;382(9):814–824.
Alikhan A., Felsten L.M., Daly M., et al. Vitiligo: A comprehensive review and update. J Am Acad Dermatol. 2011;65(3):473–491.
Krüger C., Schallreuter K.U. A review of the worldwide prevalence of vitiligo in children/adults. Int J Dermatol. 2022;61(2):142–148.
Bergqvist C., Ezzedine K. Vitiligo: A review on diagnosis and management. Dermatology. 2020;236(6):571–592.
Harris J.E. Cellular mechanisms and immune-mediated destruction of melanocytes in vitiligo. J Invest Dermatol. 2018;138(2):261–271.
Rodrigues M., Ezzedine K., Hamzavi I., et al. New insights into vitiligo pathogenesis and treatment. Lancet. 2017;389(10072):498–510.
Laddha N.C., Dwivedi M., Begum R. Increased Th1 and Th17 responses in vitiligo patients. Pigment Cell Melanoma Res. 2020;33(1):14–26.
Rashighi M., Agarwal P., Richmond J.M., et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med. 2014;6(223):223ra23.
Wang X., Du J., Wang T., et al. Roles of the IFN-γ/CXCL10 axis in vitiligo pathogenesis. Exp Dermatol. 2020;29(9):874–880.
Speeckaert R., Dugardin J., Lambert J., et al. Altered serum cytokine profiles in patients with vitiligo: A systematic review. Autoimmun Rev. 2021;20(2):102798.
Thor G., Gey A., Christen-Zaech S. Features of metabolic syndrome in patients with vitiligo. Dermatology. 2020;236(4):327–335.
Aksoy B., Kocatürk E., Şentürk B., et al. Association between vitiligo and metabolic syndrome: A clinical study. Clin Exp Dermatol. 2019;44(8):e256–e262.
Saleh H.A., Abdel Fattah N.S., Abd Elaziz N.A. Metabolic-inflammatory interactions in vitiligo: Correlation with insulin resistance. J Dermatol Sci. 2021;101(1):32–39.
Schallreuter K.U., Moore J., Wood J.M., et al. Involvement of oxidative stress in vitiligo. Free Radic Biol Med. 2019;151:116–128.
Dell’Anna M.L., Picardo M. Mitochondrial impairment in vitiligo. J Dermatol Sci. 2021;102(2):89–96.
Bhatnagar A., Singh R., Khanna N. Vitamin D pathways in melanocyte biology and vitiligo. J Steroid Biochem Mol Biol. 2020;200:105–114.
Makhmudov F., Rakhimova N., Tolibov M. Regional immunometabolic risk factors in pigmented dermatoses of Central Asia. Central Asian Medical Journal. 2023;29(4):112–120.